Hyperglycemia is the strongest risk factor contributing to the pathogenesis of DME, leading modifications in biochemical pathways including diacylglycerol (DAG)–protein kinase C (PKC), advanced glycation end products/receptor for advanced glycation end products, polyol (sorbitol), and hexosamine pathways [21]. Here, PRRT2 is linked to Hyperglycemia.